BACKGROUND: Angiopoietin-2 is expressed in prostate cancer (PCa) bone, liver, and lymph node metastases, whereas, its competitor angiopoietin-1 has limited expression in these tissues. Therefore, we hypothesized that the inhibition of angiopoietin-2 activity in PCa will impede angiogenesis, tumor growth, and alter bone response in vivo. METHODS: To test our hypothesis we used L1-10, a peptide-Fc fusion that inhibits interactions between angiopoietin-2 and its receptor tie2. We blocked angiopoietin-2 activity using L1-10 in established subcutaneous and intra-tibial LuCaP 23.1 xenografts. We then determined the effect of L1-10 on survival, tumor growth, serum PSA, proliferation, microvessel density, and angiogenesis-associated gene expression in subcutaneous tumors. We also determined serum PSA, tumor area, and bone response in intra-tibial tumors. RESULTS: The administration of L1-10 decreased tumor volume and serum PSA, and increased survival in SCID mice bearing subcutaneous LuCaP 23.1 tumors. Histomorphometric analysis, showed a further significant decrease in tumor epithelial area within the L1-10 treated LuCaP 23.1 subcutaneous tumors (P=0.0063). There was also a significant decrease in cell proliferation (P=0.012), microvessel density (P=0.012), and a significant increase in ANGPT-2 and HIF-1α mRNA expression (P≤0.05) associated with L1-10 treatment. Alternatively, in LuCaP 23.1 intra-tibial tumors L1-10 treatment did not significantly change serum PSA, tumor area or bone response. CONCLUSIONS: Our results demonstrate that inhibiting angiopoietin-2 activity impedes angiogenesis and growth of LuCaP 23.1 PCa xenografts. Based on these data, we hypothesize that angiopoietin-2 inhibition in combination with other therapies may represent a potential therapy for patients with metastatic disease.
BACKGROUND:Angiopoietin-2 is expressed in prostate cancer (PCa) bone, liver, and lymph node metastases, whereas, its competitor angiopoietin-1 has limited expression in these tissues. Therefore, we hypothesized that the inhibition of angiopoietin-2 activity in PCa will impede angiogenesis, tumor growth, and alter bone response in vivo. METHODS: To test our hypothesis we used L1-10, a peptide-Fc fusion that inhibits interactions between angiopoietin-2 and its receptor tie2. We blocked angiopoietin-2 activity using L1-10 in established subcutaneous and intra-tibial LuCaP 23.1 xenografts. We then determined the effect of L1-10 on survival, tumor growth, serum PSA, proliferation, microvessel density, and angiogenesis-associated gene expression in subcutaneous tumors. We also determined serum PSA, tumor area, and bone response in intra-tibial tumors. RESULTS: The administration of L1-10 decreased tumor volume and serum PSA, and increased survival in SCIDmice bearing subcutaneous LuCaP 23.1 tumors. Histomorphometric analysis, showed a further significant decrease in tumor epithelial area within the L1-10 treated LuCaP 23.1 subcutaneous tumors (P=0.0063). There was also a significant decrease in cell proliferation (P=0.012), microvessel density (P=0.012), and a significant increase in ANGPT-2 and HIF-1α mRNA expression (P≤0.05) associated with L1-10 treatment. Alternatively, in LuCaP 23.1 intra-tibial tumorsL1-10 treatment did not significantly change serum PSA, tumor area or bone response. CONCLUSIONS: Our results demonstrate that inhibiting angiopoietin-2 activity impedes angiogenesis and growth of LuCaP 23.1 PCa xenografts. Based on these data, we hypothesize that angiopoietin-2 inhibition in combination with other therapies may represent a potential therapy for patients with metastatic disease.
Authors: Eva Corey; Janna E Quinn; Franck Bladou; Lisha G Brown; Martine P Roudier; Julie M Brown; Kent R Buhler; Robert L Vessella Journal: Prostate Date: 2002-06-01 Impact factor: 4.104
Authors: F A Ferrer; L J Miller; R I Andrawis; S H Kurtzman; P C Albertsen; V P Laudone; D L Kreutzer Journal: Urology Date: 1998-01 Impact factor: 2.649
Authors: W J Ellis; R L Vessella; K R Buhler; F Bladou; L D True; S A Bigler; D Curtis; P H Lange Journal: Clin Cancer Res Date: 1996-06 Impact factor: 12.531
Authors: Jonathan Oliner; Hosung Min; Juan Leal; Dongyin Yu; Shashirekha Rao; Edward You; Xiu Tang; Haejin Kim; Susanne Meyer; Seog Joon Han; Nessa Hawkins; Robert Rosenfeld; Elyse Davy; Kevin Graham; Frederick Jacobsen; Shirley Stevenson; Joanne Ho; Qing Chen; Thomas Hartmann; Mark Michaels; Michael Kelley; Luke Li; Karen Sitney; Frank Martin; Ji-Rong Sun; Nancy Zhang; John Lu; Juan Estrada; Rakesh Kumar; Angela Coxon; Stephen Kaufman; James Pretorius; Sheila Scully; Russ Cattley; Marc Payton; Steve Coats; Linh Nguyen; Binodh Desilva; Anthony Ndifor; Isaac Hayward; Robert Radinsky; Tom Boone; Richard Kendall Journal: Cancer Cell Date: 2004-11 Impact factor: 31.743
Authors: Maija P Valta; Hongjuan Zhao; Matthias Saar; Johanna Tuomela; Rosalie Nolley; Johannes Linxweiler; Jouko Sandholm; Jaakko Lehtimäki; Pirkko Härkönen; Ilsa Coleman; Peter S Nelson; Eva Corey; Donna M Peehl Journal: Clin Exp Metastasis Date: 2016-02-12 Impact factor: 5.150
Authors: Sarah R Young; Matthias Saar; Jennifer Santos; Holly M Nguyen; Robert L Vessella; Donna M Peehl Journal: Prostate Date: 2013-06-06 Impact factor: 4.104
Authors: Jin Song; Shiyong Ma; Lori J Sokoll; Rodrigo V Eguez; Naseruddin Höti; Hui Zhang; Phaedre Mohr; Renu Dua; Dattatraya Patil; Kristen Douglas May; Sierra Williams; Rebecca Arnold; Martin G Sanda; Daniel W Chan; Zhen Zhang Journal: Theranostics Date: 2021-04-15 Impact factor: 11.556